Literature DB >> 18361449

The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18.

Joan K Morris1, George M Savva.   

Abstract

The objective of this study is to determine the risk of fetal loss (spontaneous abortion or stillbirth) following a prenatal diagnosis of trisomy 13 (T13; Patau syndrome) or trisomy 18 (T18; Edwards syndrome). Five regional congenital anomaly registers in England and Wales provided details on the outcomes of 198 pregnancies prenatally diagnosed with T13 and 538 prenatally diagnosed with T18. For each pregnancy the time from prenatal diagnosis until birth, miscarriage or termination occurred was calculated and these times were analyzed using Kaplan-Meier survival functions. Our results showed that between 12 weeks gestation and term an estimated 49% (95% CI: 29-73%) of pregnancies diagnosed with T13 and 72% (61-81%) of pregnancies diagnosed with T18 ended in a miscarriage or stillbirth. Between 18 weeks and term the proportions were 42% (18-72%) for T13 and 65% (57-79%) for T18 and between 24 weeks and term the proportions were 35% (5-70%) for T13 and 59% (49-77%) for T18. Male fetuses with T18 appeared to be more likely to be lost than female fetuses. These are the most precise estimates currently available for the risk of loss in a general population. These estimates should be useful in counseling women who are carrying an affected fetus and knowing the risk of fetal loss is essential to compare the performance of prenatal screening programs occurring in the first and second trimester. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18361449     DOI: 10.1002/ajmg.a.32220

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  23 in total

1.  Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening.

Authors:  Maria Loane; Joan K Morris; Marie-Claude Addor; Larraitz Arriola; Judith Budd; Berenice Doray; Ester Garne; Miriam Gatt; Martin Haeusler; Babak Khoshnood; Kari Klungsøyr Melve; Anna Latos-Bielenska; Bob McDonnell; Carmel Mullaney; Mary O'Mahony; Annette Queisser-Wahrendorf; Judith Rankin; Anke Rissmann; Catherine Rounding; Joaquin Salvador; David Tucker; Diana Wellesley; Lyubov Yevtushok; Helen Dolk
Journal:  Eur J Hum Genet       Date:  2012-06-20       Impact factor: 4.246

2.  Parent Perspectives of Support Received from Physicians and/or Genetic Counselors Following a Decision to Continue a Pregnancy with a Prenatal Diagnosis of Trisomy 13/18.

Authors:  Stephanie E Wallace; Sara Gilvary; Michael J Smith; Siobhan M Dolan
Journal:  J Genet Couns       Date:  2017-10-27       Impact factor: 2.537

3.  Transcriptomic analysis of cell-free fetal RNA suggests a specific molecular phenotype in trisomy 18.

Authors:  Keiko Koide; Donna K Slonim; Kirby L Johnson; Umadevi Tantravahi; Janet M Cowan; Diana W Bianchi
Journal:  Hum Genet       Date:  2010-12-09       Impact factor: 4.132

4.  Noninvasive Prenatal Testing for Trisomies 21, 18, and 13, Sex Chromosome Aneuploidies, and Microdeletions: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2019-02-19

5.  Patterns of congenital anomalies among individuals with trisomy 13 in Texas.

Authors:  Diego Diaz; Renata H Benjamin; Maria Luisa Navarro Sanchez; Laura E Mitchell; Peter H Langlois; Mark A Canfield; Han Chen; Angela E Scheuerle; Christian P Schaaf; Daryl A Scott; Hope Northrup; Joseph W Ray; Scott D McLean; Michael D Swartz; Katherine L Ludorf; Philip J Lupo; A J Agopian
Journal:  Am J Med Genet A       Date:  2021-03-22       Impact factor: 2.578

6.  A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States.

Authors:  Brandon S Walker; Richard E Nelson; Brian R Jackson; David G Grenache; Edward R Ashwood; Robert L Schmidt
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

7.  Massive interstitial copy-neutral loss-of-heterozygosity as evidence for cancer being a disease of the DNA-damage response.

Authors:  Yogesh Kumar; Jianfeng Yang; Taobo Hu; Lei Chen; Zhi Xu; Lin Xu; Xiao-Xia Hu; Gusheng Tang; Jian-Min Wang; Yi Li; Wai-Sang Poon; Weiqing Wan; Liwei Zhang; Wai-Kin Mat; Frank W Pun; Peggy Lee; Timothy H Y Cheong; Xiaofan Ding; Siu-Kin Ng; Shui-Ying Tsang; Jin-Fei Chen; Peng Zhang; Shao Li; Hong-Yang Wang; Hong Xue
Journal:  BMC Med Genomics       Date:  2015-07-25       Impact factor: 3.063

8.  Perinatal management of trisomy 18: a survey of obstetricians in Australia, New Zealand and the UK.

Authors:  D J C Wilkinson; L de Crespigny; C Lees; J Savulescu; P Thiele; T Tran; A Watkins
Journal:  Prenat Diagn       Date:  2013-10-30       Impact factor: 3.050

9.  DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study.

Authors:  Glenn E Palomaki; Cosmin Deciu; Edward M Kloza; Geralyn M Lambert-Messerlian; James E Haddow; Louis M Neveux; Mathias Ehrich; Dirk van den Boom; Allan T Bombard; Wayne W Grody; Stanley F Nelson; Jacob A Canick
Journal:  Genet Med       Date:  2012-02-02       Impact factor: 8.822

Review 10.  The trisomy 18 syndrome.

Authors:  Anna Cereda; John C Carey
Journal:  Orphanet J Rare Dis       Date:  2012-10-23       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.